The PIM kinase inhibitor TP-3654 demonstrates efficacy in a murine model of myelofibrosis

被引：2

作者：

Dutta, Avik ^{[1
]}

Nath, Dipmoy ^{[1
]}

Yang, Yue ^{[1
]}

Mohi, Golam ^{[1
]}

机构：

[1] Univ Virginia, Charlottesville, VA USA

来源：

CANCER RESEARCH | 2018年 / 78卷 / 13期

关键词：

D O I：

10.1158/1538-7445.AM2018-1874

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1874

引用

页数：2

共 50 条

[31] Proteasome inhibitor bortezomib can inhibit bone marrow fibrosis development in a murine model of myelofibrosis.
Wagner-Ballon, O
Gastinne, T
Tulliez, M
Lacout, C
Pisani, D
Chagraoui, H
Villeval, JL
Vainchenker, W
Giraudier, S
BLOOD, 2005, 106 (11) : 726A - 726A
[32] AMN107: Efficacy of the selective Bcr-Abl tyrosine kinase inhibitor in a murine model of chronic myelogenous leukemia
Jensen, Michael R.
Bruggen, Josef
Dilea, Clifford
Mestan, Jurgen
Manley, Paul W.
CANCER RESEARCH, 2006, 66 (08)
[33] Preclinical efficacy of the novel PIM2 kinase inhibitor, JP_11646, in human acute leukemia models
Pundt, Krista E.
Baldino, Carmen M.
Caserta, Justin
Dumas, Stephane
Flanders, Yvonne
Wang, Eunice S.
Fetterly, Gerald J.
CANCER RESEARCH, 2014, 74 (19)
[34] Identification of PIM447, a potent and selective proviral insertion site of Moloney murine leukemia (PIM) 1,2 and 3 kinase inhibitor in clinical trials for cancer
Burger, Matthew
Nishiguchi, Gisele
Han, Wooseok
Lan, Jiong
Simmons, Robert
Atallah, Gordana
Tamez, Victoriano
Zhang, Yanchen
Ding, Yu
Mathur, Michelle
Muller, Kristine
Bellamacina, Cornelia
Lindvall, Mika
Zang, Richard
Huh, Kay
Dai, Yumin
Ginn, Elaine
Aycinena, Alex
Langowski, John
Lambert, Amy
Fritsch, Christine
Kauffmann, Audry
Pfister, Estelle
Garcia, Pablo
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2015, 250
[35] Development of a murine orthotopic model of leukemia:: Evaluation of TP53 gene therapy efficacy
Bossi, G
Scardigli, R
Musiani, P
Martinelli, R
Gentileschi, MP
Soddu, S
Sacchi, A
CANCER GENE THERAPY, 2000, 7 (01) : 135 - 143
[36] Development of a murine orthotopic model of leukemia: Evaluation of TP53 gene therapy efficacy
Gianluca Bossi
Raffaella Scardigli
Piero Musiani
Roberta Martinelli
Maria Pia Gentileschi
Silvia Soddu
Ada Sacchi
Cancer Gene Therapy, 2000, 7 : 135 - 143
[37] The IMPDH inhibitor VX-944 demonstrates in vivo efficacy in an aggressive leukemia model.
Jain, J
Ma, JG
Furey, B
Recher, C
Demur, C
Poondru, S
Zhang, JB
Li, SL
Firestone, B
Olson, K
Murphy, M
Taylor, J
Henkel, G
Ball, E
Yao, YM
Almquist, S
Hoover, R
BLOOD, 2004, 104 (11) : 693A - 694A
[38] Discovery of Selective Small Molecule Pan-Pim Kinase Inhibitors with Potent Oral Efficacy in Murine Xenograft Models.
O'Brien, Sean
Haddach, Mustapha
Borsan, Cosmin
Michaux, Jerome
Kerdoncuff, Pauline
Schwaebe, Mike
Pierre, Fabrice
Stefan, Eric
Nedelle, Anne Sophie
Siddiqui-Jain, Adam
Streiner, Nicole
Macalino, Diwata
Drygin, Denis
Ho, Caroline
Bliesath, Josh
Omori, May
Stansfield, Ryan
Phung, Jennifer
Ryckman, David
Rice, William
Anderes, Kenna
BLOOD, 2009, 114 (22) : 687 - 688
[39] TAS5315, A NOVEL BRUTON'S TYROSINE KINASE INHIBITOR, DEMONSTRATES POTENT EFFICACY AGAINST BONE DESTRUCTION IN AN ANIMAL MODEL FOR RHEUMATOID ARTHRITIS
Noma, Naruto
Hosoi, Fumihito
Iguchi, Satoru
Kaneko, Ryusuke
Yoshiga, Yohei
Arima, Yasunobu
Akasaka, Daichi
Tanaka, Kenji
Saito, Akihiro
Utsugi, Teruhiro
Ikizawa, Koichi
ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1092 - 1092
[40] TAS5315, A NOVEL BRUTON'S TYROSINE KINASE (BTK) INHIBITOR, DEMONSTRATES POTENT EFFICACY IN MOUSE COLLAGEN-INDUCED ARTHRITIS MODEL
Hosoi, F.
Iguchi, S.
Yoshiga, Y.
Kaneko, R.
Nakachi, Y.
Akasaka, D.
Yonekura, K.
Iwasawa, Y.
Sasaki, E.
Utsugi, T.
ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 97 - 97

← 1 2 3 4 5 →